
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is projected to have a strong financial future due to their innovative technology, platform potential, and promising pipeline, specifically agenT-797 for treatment of NSCLC and gastric cancer with 10% and 15% probability of success, respectively. However, risks include safety signals or lower-than-expected efficacy in clinical programs, potential commercial competition, regulatory concerns, and financing needs.
Bears say
MiNK Therapeutics is currently valued at $0.67 billion and has a Buy rating and a $35 price target based on a discounted cash flow analysis, with risks to price target achievement including safety concerns, lower-than-expected clinical efficacy, and commercial competition. Furthermore, updates on their IPF trial are expected later in 2026, which could potentially expand the company's development into end stage idiopathic pulmonary fibrosis, supported by promising preclinical data. However, the company faces de-listing risk if shares drop below $1 and may require additional financing, with a projected cash runway into 2027.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares